Statement Of Changes In Equity [Abstract]

ABIONYX Pharma - Filing #2810725

Concept As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity
158,000 EUR
7 922 EUR
6 341 EUR
12 572 EUR
1 623 EUR
103,000 EUR
193,000 EUR
7 169 EUR
192,000 EUR
8 599 EUR
2 937 EUR
229,000 EUR
1 418 EUR
126,000 EUR
201,000 EUR
169 829 EUR
10 677 EUR
10,000 EUR
179 214 EUR
87,000 EUR
1 396 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)
3 518 EUR
0 EUR
0 EUR
3 518 EUR
0 EUR
0 EUR
0 EUR
0 EUR
4 206 EUR
0 EUR
4 206 EUR
0 EUR
0 EUR
0 EUR
Comprehensive income
3 575 EUR
3 985 EUR
Increase (decrease) through other changes, equity
94,000 EUR
0 EUR
0 EUR
94,000 EUR
0 EUR
0 EUR
0 EUR
Increase (decrease) through treasury share transactions, equity
36,000 EUR
36,000 EUR
0 EUR
0 EUR
0 EUR
0 EUR
0 EUR
0 EUR
28,000 EUR
28,000 EUR
0 EUR
0 EUR
0 EUR
0 EUR
Increase (decrease) through share-based payment transactions, equity
20,000 EUR
0 EUR
0 EUR
20,000 EUR
0 EUR
0 EUR
0 EUR
0 EUR
505,000 EUR
0 EUR
505,000 EUR
0 EUR
0 EUR
0 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.